Lonza 4D-Nucleofector LV Unit PRO electroporation unit

Lonza’s 4D-Nucleofector LV Unit PRO is a next-generation, large-scale electroporation unit designed to deliver clinically relevant cargos into large volumes of T cells. The unit builds on the company’s non-viral large-scale transfection platform and is optimised for CRISPR-based genome engineering and other advanced cell therapy applications.

For more than 20 years, Lonza’s Nucleofector Technology has been used in cell and gene therapy R&D, enabling efficient delivery into hard-to-transfect primary cells, such as T cells. The 4D-Nucleofector LV Unit PRO further advances this technology, offering enhanced performance for CRISPR-based knock-out, knock-in and transposition.

A key innovation is the implementation of the Nucleocuvette Cartridges PRO, an improved cartridge version that enables the electroporation of complex cargos into up to one billion cells per run. The updated cartridge supports complex clinically relevant cargo delivery and introduces several usability improvements, including greater flexibility, simplified loading and clearing, and increased robustness of the flow-through process.

The upgraded system is suitable for preclinical studies and process development, serving as a scalable and reproducible platform for a seamless translation from discovery projects to GMP-compliant manufacturing for next-generation cell and gene therapies.